[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100410907":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":10,"locations":16,"responsibleParty":38,"collaborators":41,"id":44,"slug":10,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":18,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with a previous diagnosis of ADPKD",null,"Patients that have been diagnosed with ADPKD and are classified as Class 1A, 1B, 1C, 1D and 1E.",[13],{"name":14,"affiliation":5,"role":15},"Maria V Irazabal, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[17],{"facility":5,"status":18,"city":19,"state":20,"zip":21,"country":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"RECRUITING","Rochester","Minnesota","55905","United States",{"type":24,"coordinates":25},"Point",[26,27],-92.4699,44.02163,{"lat":27,"lon":26},[30,34,37],{"name":31,"role":32,"phone":10,"phoneExt":10,"email":33},"Ahmed Abdelfattah","CONTACT","Abdelfattah.Ahmed@mayo.edu",{"name":14,"role":32,"phone":35,"phoneExt":10,"email":36},"507-884-5628","irazabalmira.maria@mayo.edu",{"name":14,"role":15,"phone":10,"phoneExt":10,"email":10},{"type":15,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Maria V. Irazabal Mira","Principal Investigator",[42],{"name":43,"class":6},"Polycystic Kidney Disease Foundation","100410907",false,"NCT04630613","NOX4 and Related Biomarkers in ADPKD","NOX4, Mitochondria and Related Biomarkers in Autosomal Dominant Polycystic Kidney Disease","Inclusion Criteria:\n\n* ADPKD (based on Ravine et al. criteria)\n* Class 1 A-E according to imaging classification\n* Male and female subjects 15 - 40 years of age\n* Estimated GFR\\> 70 mL\u002Fmin\u002F1.73 m2 (CKD-EPI)\n* Ability to provide written, informed consent\n\nExclusion Criteria:\n\n* Class 2 according to imaging classification\n* Concomitant systemic disease affecting the kidney\n* Diabetes mellitus\n* Predicted urine protein excretion in \\>1 g\u002F24 hrs\n* Use of antioxidants i.e. vitamins, Nrf2 activators\n* Abnormal urinalysis","ALL","15 Years","40 Years",{"count":54,"type":55},60,"ESTIMATED","2 Years","OBSERVATIONAL","To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).",[60],"Autosomal Dominant Polycystic Kidney Disease",[62,63,64],"Oxidative Stress","Mitochondria injury and function","NADPH oxidase 4","2026-01-07",{"date":67,"type":68},"2026-01-09","ACTUAL",{"date":70,"type":68},"2020-07-21",{"date":72,"type":55},"2027-01",{"name":5,"class":6},1]